CD47
Leukocyte surface antigen CD47
As of the edition of 20 October 2026, CD47 (leukocyte surface antigen CD47, UniProt Q08722) has 17 drugs tested at it and 27 companies on the list, 12 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q08722
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 15
- Disease areas
- Cancer; Blood and lymph; Immune system; Digestive system; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue
- Registered trials of its drugs
- 109
Drugs at this target
| Status | Count |
|---|---|
| Active | 5 |
| Went quiet | 1 |
| Stopped | 8 |
| Status not established | 3 |
| Total | 17 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Magrolimab | Active | Phase 3 | none listed |
| Evorpacept | Active | Phase 3 | none listed |
| AK117 | Active | Phase 2 | none listed |
| Maplirpacept | Stopped | Phase 2 | none listed |
| IBI-188 | Stopped | Phase 2 | none listed |
| IMM-0306 | Active | Phase 3 | none listed |
| Lemzoparlimab | Stopped | Phase 3 | none listed |
| HCB101 | Active | Phase 2 | none listed |
| HX009 | Status not established | Phase 2 | none listed |
| AO-176 | Status not established | Phase 2 | none listed |
| CC-90002 | Went quiet | Phase 1 | none listed |
| Vislarafusp alfa | Stopped | Phase 2 | none listed |
12 of 17 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 12 |
| Engaged | 11 |
| Undetermined | 4 |
| Total on the list | 27 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Bristol Myers Squibb | Route A |
| TJ Biopharma | Route A |
The other 24 companies at CD47
In the product27 companies in all; 24 are not named here, and no score is.
See the 27 companies at CD47, ranked, with the facts behind eachRequest access. Nothing is shown until you do.